funded by the National Natural Science Foundation of China grant 81700148 and Natural Science Foundation of Guangdong Province grant 2021A1515010093 and 2023A1515011862;funded by the National Natural Science Foundation of China grant 82170181;funded by the Basic and Applied Basic Research Foundation of Guangdong Province grant 2022B1515120087.
Objectives:The optimal treatment strategy for early-stage natural killer/T-cell lymphoma(NKTCL)remains unclear.This study aimed to evaluate and compare the clinical outcomes and adverse events(AEs)associated with two ...